Adimmune Corporation · TWSE:4142
Adimmune — 2023 Institutional Investors' Conference
10 slides from Adimmune's conference presentation, 2023
Slide 1: 2023 Institutional Investors' Conference
2023 TWSE: 4142 Institutional Investors’ Conference Adimmune Corporation
Slide 2: Disclaimer
Disclaimer • Adimmune has not released any financial forecast. Business and financial information presented in this brief and during the Q&A session, should they concern business operation or industrial development, may differ materially from actual results. These discrepancies are due to such risks
Slide 3: FY2023 Q3 Consolidated Income Statement
FY2023 Q3 Consolidated Income Statement Unit：NT$ Thousands 2023.Q3 2022.Q3 Items Reviewed % Reviewed % Sales Revenues 973,345 1,087,289 Operating Costs (488,399) (531,705) Net operating margin 484,946 50% 555,584 51% Operating expenses (285,873) (202,076) Selling expenses (7,585) (40,225) General an
Slide 4: FY2023 Q1-Q3 Consolidated Income Statement
FY2023 Q3 Consolidated Income Statement Unit：NT$ Thousands 2023.Q1-Q3累計 2022.Q1-Q3累計 Items Reviewed % Reviewed % Sales Revenues 1,225,604 1,667,022 Operating Costs (895,927) (1,015,229) Net operating margin 329,677 27% 651,793 39% Operating expenses (668,624) (586,535) Selling expenses (70,159) (139
Slide 5: Revenues Generated from Global Market
Revenues Generated from Global Market
Slide 6: Revenues Growth from CDMO Services
Revenues Growth from CDMO Services
Slide 7: Corporate Development Plan
Corporate Development Plan To continue exploring overseas markets for quadrivalent influenza vaccine • Southern hemisphere market (Brazil), Middle East, and South Asia Co-development and technology transfer of new products with strategic partners • Multivalent enterovirus vaccine (Europe), 5-in-
Slide 8: Research & Development Projects
Emergency Production Capacity Production during Scaling-Up of EV71 Pandemic Flu Vaccine In the case of the H7N9 • To start the vaccine, a Mock-up commercialization of program for the cell-based production of EV71 vaccine at the Research & parameters of commercial scale is established and Tanzi campu
Slide 9: Q&A
Q&A
Slide 10: Thank You
THANK OFFICE No. 3, Sec. 1, Tanxing Rd., YOU Tanzi Dist., Taichung City 427003 , Taiwan (R.O.C.) +886-4-25381220 https://www.adimmune.com. We look forward to working with you tw/en TWSE: 4142